Pregabalin controlled-release - GL PharmTech

Drug Profile

Pregabalin controlled-release - GL PharmTech

Alternative Names: GLA5PR; GLA5PR GLARS; GLA5PR GLARS-NF1; GLA5PR GLARS-NF1 Tab; GLA5PR GLARS-NF3; Pregabalin GLARS; Pregabalin QD

Latest Information Update: 24 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GL PharmTech
  • Developer Daewon Pharmaceutical; GL PharmTech
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Neuropathic pain
  • Phase I Pain

Most Recent Events

  • 24 Jul 2017 GL PharmTech has patent protection for oral pregabalin sustained-release triple layer tablet in Japan, European Union and USA, before July 2017 (GL PharmTech website, July 2017)
  • 01 Apr 2017 GL Pharm Tech Corporation completes a phase I bioequivalence trial in Healthy volunteers in South Korea (PO, Tablet) (NCT02952937)
  • 01 Apr 2017 GL Pharm Tech Corporation completes a phase I bioequivalence trial in Healthy volunteers in South Korea (PO, Tablet) (NCT02955472)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top